Flupirtine
Overview[edit]
Flupirtine is a non-opioid analgesic that was primarily used for the treatment of acute and chronic pain. It is known for its unique mechanism of action as a selective neuronal potassium channel opener, which contributes to its analgesic and muscle relaxant properties.
Mechanism of Action[edit]
Flupirtine functions by opening neuronal potassium channels, specifically the Kv7 (KCNQ) family of channels. This action leads to the stabilization of the neuronal membrane potential and a reduction in neuronal excitability. By modulating the activity of these channels, flupirtine indirectly inhibits the release of excitatory neurotransmitters, thereby exerting its analgesic effects.
Pharmacokinetics[edit]
Flupirtine is administered orally and is well absorbed from the gastrointestinal tract. It undergoes extensive hepatic metabolism, primarily through the process of N-acetylation. The drug and its metabolites are excreted mainly via the kidneys. The half-life of flupirtine is approximately 6 to 8 hours, allowing for multiple daily dosing.
Clinical Uses[edit]
Flupirtine was used in the management of various types of pain, including:
- Acute pain, such as postoperative pain
- Chronic pain, including musculoskeletal pain and tension headaches
- Neuropathic pain
Side Effects[edit]
Common side effects of flupirtine include:
- Drowsiness
- Dizziness
- Nausea
- Fatigue
In rare cases, flupirtine has been associated with severe liver damage, which led to its withdrawal from the market in several countries.
Regulatory Status[edit]
Due to concerns over hepatotoxicity, the use of flupirtine has been restricted or banned in many regions. The European Medicines Agency (EMA) recommended the suspension of marketing authorizations for flupirtine-containing medicines in 2018.
